The first clinical trial of an MF59®-adjuvanted influenza vaccine (Novartis) was conducted
20 years ago in 1992. The product that emerged (Fluad®, Novartis) was licensed first in Italy …

Vaccination remains the most effective prophylactic intervention for infectious disease in the
healthcare professional's toolkit. However, the efficacy and effectiveness of vaccines …

Aging results in profound immune dysfunction, resulting in the decline of vaccine
responsiveness previously attributed to irreversible defects in the immune system. In …

Protection against influenza is mediated by neutralizing antibodies, and their induction at
high and sustained titers is key for successful vaccination. Optimal B cells activation requires …

Vaccines represent the most efficient tool for preventing diseases caused by infectious
pathogens. During the last century significant progress has been made in vaccine …

Novel adjuvants are highly demanded to aid in development of improved or new vaccines
against existing or emerging infectious diseases. Considering commonly used Alum and …

There is an urgent need to improve protective responses to influenza vaccination in the
elderly population, which is at especially high risk for adverse outcomes from influenza …

Because of the age-related immune system decline, 2 potentiated influenza vaccines were
specifically licensed for the elderly: Fluad®, an MF59-adjuvanted vaccine administered …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the
associated coronavirus disease 2019 (COVID-19), which severely affect the respiratory …

Background. Despite vaccination, residents of long-term-care facilities (LTCFs) remain at
high risk of influenza-related morbidity and mortality. More-effective vaccine options for this …